ALX Oncology has been granted a patent for a polypeptide that targets cancer cells and increases phagocytosis. The polypeptide includes a high affinity SIRP-a D1 domain that binds CD47 with higher affinity than the wild-type SIRP-a. The polypeptide does not cause acute anemia after administration. GlobalData’s report on ALX Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ALX Oncology, personalized cancer vaccines was a key innovation area identified from patents. ALX Oncology's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A polypeptide that targets and eliminates cancer cells
A recently granted patent (Publication Number: US11639376B2) discloses a polypeptide that has the potential to treat various diseases and disorders, including cancer, autoimmune diseases, and inflammatory diseases. The polypeptide consists of a signal-regulatory protein a (SIRP-a) polypeptide or a fragment thereof that can bind to CD47, along with an Fc variant. The Fc variant is a human IgG1 Fc region with specific mutations (L234A, L235A, G237A, and N297A) that prevent acute anemia in rodents, non-human primates, and humans after administration.
The patent also describes a method of treating individuals with diseases or disorders by administering the polypeptide. The diseases or disorders that can be targeted include various types of cancer (solid tumor cancer, hematological cancer, leukemia, lymphoma, sarcoma, glioma, etc.), autoimmune diseases (multiple sclerosis, rheumatoid arthritis, lupus, etc.), and inflammatory diseases (psoriasis, atherosclerosis, asthma, etc.).
The SIRP-a polypeptide or fragment thereof that binds to CD47 is specified to have a particular amino acid sequence, and it can also have other sequences listed in the patent. The method of treatment can involve the administration of additional agents, such as antibodies, tumor-associated antigens, or non-antibody therapeutics. Multiple agents can be administered, including combinations of antibodies or an antibody and a tumor-associated antigen.
The patent also covers a nucleic acid encoding the polypeptide, a vector containing the nucleic acid, and a host cell comprising the nucleic acid for the production of the polypeptide. Furthermore, a pharmaceutical composition comprising the polypeptide and a pharmaceutically acceptable carrier is disclosed.
Additionally, the patent describes a dimer of the polypeptide, which can be a heterodimer or a homodimer. The dimer retains the binding capabilities of the individual polypeptides.
Overall, this granted patent presents a polypeptide and its various applications in the treatment of diseases and disorders, particularly cancer, autoimmune diseases, and inflammatory diseases. The polypeptide's unique composition and binding properties make it a promising candidate for therapeutic interventions.
To know more about GlobalData’s detailed insights on ALX Oncology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
